istock-629794242xesai-1

Xesai / iStockphoto.com

7 June 2018Big Pharma

GSK completes buyout of Novartis from joint venture

GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More on this story

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More on this story

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB